Balance Sheet
Accounts PayablesAccumulated DepreciationAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - AccuredReceivables - NetRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Kura Oncology (KURA) Total Liabilities (2022 - 2026)

Kura Oncology has reported Total Liabilities over the past 5 years, most recently at $544.7 million for Q1 2026.

  • Quarterly Total Liabilities rose 43.58% to $544.7 million in Q1 2026 from the year-ago period, while the trailing twelve-month figure was $544.7 million through Mar 2026, up 43.58% year-over-year, with the annual reading at $564.2 million for FY2025, 62.83% up from the prior year.
  • Total Liabilities was $544.7 million for Q1 2026 at Kura Oncology, down from $564.2 million in the prior quarter.
  • Over five years, Total Liabilities peaked at $564.2 million in Q4 2025 and troughed at $30.8 million in Q1 2023.
  • The 5-year median for Total Liabilities is $53.4 million (2023), against an average of $212.1 million.
  • Year-over-year, Total Liabilities grew 25.62% in 2024 and then soared 676.99% in 2025.
  • A 5-year view of Total Liabilities shows it stood at $36.0 million in 2022, then skyrocketed by 43.39% to $51.7 million in 2023, then surged by 570.74% to $346.5 million in 2024, then soared by 62.83% to $564.2 million in 2025, then decreased by 3.47% to $544.7 million in 2026.
  • Per Business Quant, the three most recent readings for KURA's Total Liabilities are $544.7 million (Q1 2026), $564.2 million (Q4 2025), and $406.8 million (Q3 2025).